Published research and study summaries
Advancing the science of neuromodulation for painful diabetic neuropathy through rigorous clinical research.
Active Clinical Studies
We are committed to building the evidence base for NeuroDynamics Global therapy through well-designed clinical trials.
Double-Blind, Randomized, Placebo-Controlled Trial
Presented at North American Neuromodulation Society (NAMS), S. Madhuchander, S. Gurunath (January 2019)
Enrolled 89 subjects with peripheral neuropathy caused by type 2 diabetes. Patients receiving neurostimulation treatment (fixed and sweep frequency) demonstrated a statistically significant decrease in pain (VAS), with simultaneous improvement in nerve sensory function (VPT), patient function (ONLS), and anxiety/sleep scores (p<.001). Results suggest the effects are reproducible and directly attributable to the neurostimulation treatment.
Individual results vary. Study findings are not a guarantee of outcome.
Key Outcome: 68.25% of subjects receiving stimulation showed significant pain reduction
Observational Trial — Frontiers in Neuroscience (August 2025)
Staats, P. S. et al.
Observational analysis of 83 patients over an average of 227 days, reporting pain scores during follow-up. See the publication for the study design, reported findings, and limitations.
Individual results vary. Study findings are not a guarantee of outcome.
Staats, P. S., Staats, A., Mikhaiel, B., Chen, J., Azabou, E., & Rangon, C.-M. (2025). Frontiers in Neuroscience, vol. 19, article 1644961.


Multi-Center, Prospective, Open-Label, Observational Study
Cleveland Clinic (National Principal Investigator) and Partner Sites
An approximately 6-month study consisting of about 9 study visits evaluating the reduction of diabetic neuropathic pain for subjects with type I or II diabetes who undergo percutaneous implantation of the NS100 device with continuous glucose monitoring. Approximately 50 patients will be enrolled.
Individual results vary. Study findings are not a guarantee of outcome.
The science of peripheral nerve stimulation
Peripheral electrical nerve stimulation (PENS) has been studied for decades as an approach to managing chronic pain conditions. NeuroDynamics Global builds on this foundation with a protocol specifically designed for painful diabetic neuropathy.
Neuromodulation works by delivering electrical stimulation to peripheral nerves, which may help modulate pain signaling pathways. The 20-day protocol is designed to provide therapeutic benefit that extends beyond the treatment period.
Request the clinical dossierMechanism of Action
Targeted nerve stimulation to modulate pain signals
Patient Selection
Criteria for identifying appropriate candidates
Clinical Protocol
Standardized 20-day therapy protocol
Interested in research collaboration?
We partner with leading academic medical centers. Contact us to discuss research opportunities.
Contact Research Team